Pfizer Quietly Chalks Up Another $2bn Year For Biosimilars

Bevacizumab And Trastuzumab Rivals Grow Ahead Of Adalimumab Launch

 
• By Dave Wallace

Despite annual sales that topped out at more than $2bn, Pfizer remains tight-lipped about its biosimilars interests as it looks towards a US launch this year of its Abrilada rival to Humira.

Two Billion Dollars $2bn Icon
For the second year running, Pfizer’s biosimilars sales exceeded $2bn • Source: Shutterstock

More from Biosimilars

More from Products